Masimo Corp Stock Price, News & Analysis

Masimo Corporation (NASDAQ: MASI) announced preliminary financial results for Q1 2022, expecting product revenue between $285 million and $315 million.

Supply chain issues, including critical component shortages and freight delays, led to lower-than-expected sales. The company reaffirmed its full-year revenue guidance of $1,350 million, citing strong customer demand and the belief that they will fulfill open orders throughout the year.

Masimo (NASDAQ: MASI) announced findings from a study indicating that children monitored with SpHb® experience fewer blood transfusions, less bleeding, and shorter ICU stays during fronto-orbital advancement surgery. The study, published in the Journal of Clinical Monitoring and Computing, analyzed data from 42 pediatric patients, revealing that the SpHb monitoring group had significantly lower intraoperative packed red blood cell transfusion (136.3 mL vs. 181.5 mL, p = 0.015), less postoperative surgical site drainage, and shorter ICU stays (37.1 hours vs. 64.8 hours, p < 0.001).

Masimo (NASDAQ: MASI) has expanded its Patient SafetyNet™ platform, introducing secure telehealth capabilities at the HIMSS Global Health Conference. This enhancement facilitates end-to-end audio and visual communication for remote patient monitoring, improving clinical workflows and communication efficiency. The software upgrade integrates multi-way communication, allowing real-time collaboration among clinicians. Additionally, it supports remote access to continuous patient monitoring data and enhances patient engagement by enabling virtual consultations with family members at the bedside, ultimately aiming to improve patient outcomes and reduce care costs.

Masimo has received FDA clearance for its SedLine brain function monitoring technology for pediatric patients aged 1-17 in the United States. This advancement allows for enhanced monitoring of brain activity during anesthesia, with specialized sensors designed for smaller foreheads. The SedLine system utilizes advanced signal processing of EEG signals to provide detailed insights for clinicians, aiming to improve safety and efficacy during pediatric anesthesia.

Sound United, a leader in premium audio products, has agreed to be acquired by Masimo (NASDAQ: MASI), a global medical technology company. This strategic acquisition aims to combine Masimo's healthcare strengths with Sound United's consumer electronics expertise, enhancing product distribution and consumer experience. The partnership will utilize Sound United’s extensive brand portfolio and global reach to improve Masimo's consumer product offerings. The transaction is anticipated to close in mid-2022, pending regulatory approvals.

Masimo reported a 11.0% increase in product revenue for Q4 2021, totaling $327.6 million, and an 8.3% increase for the full year, reaching $1,239.2 million. GAAP net income for Q4 was $68.3 million or $1.18 per diluted share, while full-year GAAP net income stood at $229.6 million, $3.98 per share. 2022 guidance estimates product revenue at $1,350 million. Additionally, Masimo plans to acquire Sound United for approximately $1.025 billion, expected to bolster their consumer health technology strategy.

Masimo (NASDAQ: MASI) has expanded its Masimo SafetyNet platform to incorporate advanced telehealth capabilities, allowing for robust video-based virtual consultations alongside continuous remote monitoring. This update enhances patient care by enabling clinicians to perform multi-way virtual appointments through a single smartphone app, integrating vital sign monitoring and enhanced communication tools. The platform now supports a wider range of patients, including post-surgical and chronic condition cases, streamlining care from hospital to home.

Masimo (NASDAQ: MASI) and Temple University Hospital have expanded their partnership, integrating the Centroid™ patient monitoring system across 100 ICU beds. This advanced wireless technology supports clinicians by monitoring patient position, respiratory rates, and alerting for fall-like events. Centroid aims to reduce hospital-acquired pressure injuries (HAPIs), which affect nearly 5% of hospitalized patients in the U.S., resulting in significant treatment costs. The collaboration enhances patient safety and care efficiency, marking a step forward in Masimo's commitment to improving healthcare outcomes.

Masimo (NASDAQ: MASI) reported findings from a study presented at the Society for Technology in Anesthesia 2022 Annual Meeting. The study analyzed pulse oximetry data and found no significant bias based on ethnicity among black and white subjects monitored with Masimo's SET® pulse oximetry technology. The analysis included 7,183 paired samples and revealed that the bias difference was 0.15%, which is not clinically significant. Masimo plans to conduct additional studies to further explore these findings.